

Resource Summary Report

Generated by SPARC SAWG on Sep 4, 2026

IFN-g

RRID:AB_398580

Type: Antibody

Proper Citation

BD Biosciences Cat# 554702, RRID:AB_398580

Antibody Information

URL: http://antibodyregistry.org/AB_398580

Proper Citation: BD Biosciences Cat# 554702, RRID:AB_398580

Target Antigen: IFN-?

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Intracellular staining (flow cytometry)

Antibody Name: IFN-g

Description: This monoclonal targets IFN-?

Target Organism: baboon, cynomolgus, rhesus, human

Antibody ID: AB_398580

Vendor: BD Biosciences

Catalog Number: 554702

Record Creation Time: 20231110T081107+0000

Record Last Update: 20260831T195810+0000

Ratings and Alerts

No rating or validation information has been found for IFN-g.

No alerts have been found for IFN-g.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 47 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

van Renterghem AWJ, et al. (2026) Liver metastases dampen IL18-driven ?? T cell activity and immunotherapy responsiveness in colorectal cancer. Cell reports. Medicine, 7(2), 102579.

Roy V, et al. (2026) Epstein-Barr-virus-specific functional antibody signatures in the context of nasopharyngeal carcinoma development. Med (New York, N.Y.), 7(1), 100925.

Calescibetta A, et al. (2026) Combining lenalidomide with IL-2 family of cytokines enhances activating receptor and perforin/granzyme expression in NK cells. PloS one, 21(3), e0344471.

Kirkpatrick C, et al. (2025) Isolation of mitochondrial mutation-specific T cell receptors. Journal of immunology (Baltimore, Md. : 1950).

Akhtar A, et al. (2025) Bioengineering the metabolic network of CAR T cells with GLP-1 and Urolithin A increases persistence and long-term anti-tumor activity. Cell reports. Medicine, 6(3), 102021.

Conn BP, et al. (2025) Generation of T cell responses against broad KRAS hotspot neoantigens for cell therapy or TCR discovery. Cell reports methods, 5(5), 101049.

Nikolic I, et al. (2025) Enhancing anti-tumor immunity of natural killer cells through targeting IL-15R signaling. Cancer cell.

Moore AE, et al. (2025) DAP12-associated synthetic antigen receptors enable multi-targeting of T cells with independent chimeric receptors in a small genetic payload. iScience, 28(4), 112142.

Venetz-Arenas N, et al. (2025) Development of DARPin T cell engagers for specific targeting of tumor-associated HLA/peptide complexes. iScience, 28(12), 113926.

Mattingly CLR, et al. (2025) Human lung CD8+ tissue-resident memory T cell-derived interferon-? orchestrates subset-specific antiviral programming in airway epithelial cells. Immunity, 58(12), 3006.

Dong B, et al. (2024) NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs. Cancer immunology research, 12(10), 1421.

Zhou S, et al. (2024) CD97 maintains tumorigenicity of glioblastoma stem cells via mTORC2 signaling and is targeted by CAR Th9 cells. Cell reports. Medicine, 5(12),

101844.

Montalban-Bravo G, et al. (2024) Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia. *Cell reports. Medicine*, 5(6), 101585.

Cui T, et al. (2024) Dynamic immune landscape in vaccinated-BA.5-XBB.1.9.1 reinfections revealed a 5-month protection-duration against XBB infection and a shift in immune imprinting. *EBioMedicine*, 99, 104903.

Ibáñez-Molero S, et al. (2024) Phosphoprotein dynamics of interacting T cells and tumor cells by HySic. *Cell reports*, 43(1), 113598.

Hopkins G, et al. (2024) Lower Humoral and Cellular Immunity Following Asymptomatic SARS-CoV-2 Infection Compared to Symptomatic Infection in Education (The ACE Cohort). *Journal of clinical immunology*, 44(6), 147.

Racle J, et al. (2023) Machine learning predictions of MHC-II specificities reveal alternative binding mode of class II epitopes. *Immunity*, 56(6), 1359.

Deng Y, et al. (2023) Beta-spike-containing boosters induce robust and functional antibody responses to SARS-CoV-2 in macaques primed with distinct vaccines. *Cell reports*, 42(11), 113292.

Capone S, et al. (2023) GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial. *Cell reports. Medicine*, 4(6), 101084.

Erra Diaz F, et al. (2023) Concomitant inhibition of PPAR γ and mTORC1 induces the differentiation of human monocytes into highly immunogenic dendritic cells. *Cell reports*, 42(3), 112156.